We found that blocking the CD30 pathway with anti-CD30L significantly inhibited tumor growth after 14 days in the Pd1−/− CD45.2+ Treg cell cohort compared with animals that received the isotype control. This evidence concerns the gene TNFRSF8 and neoplasm.